Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH (CandLE)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: January 23, 2008
Last updated: February 5, 2008
Last verified: January 2008
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the impact of the antihypertensive therapy with candesartan or candesartan/HCT on relevant medical parameters related to the left ventricular hypertrophy (LVH) as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension..

Essential Hypertension
Left Ventricular Hypertrophy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Essential Hypertension and a Concomitant Disease Left Ventricular Hypertrophy

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • to estimate under naturalistic conditions the impact of the antihypertensive therapy with candesartan or candesartan/HCT on pre-post change from Visit 1 to Visit 2 of Sokolow-Lyon index, Cornell index and Left Ventricular Mass Index. [ Time Frame: app. 3 monthly ]

Secondary Outcome Measures:
  • to estimate the change of the systolic and diastolic blood pressure, separately by the (maximum) prescribed daily dose of candesartan or candesartan/ HCT [ Time Frame: app. 3 monthly ]
  • to gain further insight into the occurrence of unknown, unexpected and/or rarely occurring adverse events (AE) by estimating the incidence under naturalistic conditions. [ Time Frame: app. 3 monthly ]

Enrollment: 686
Study Start Date: January 2007
Study Completion Date: October 2007
Patient with essential hypertension and LVH under treatment with candesartan or candesartan HCT


Ages Eligible for Study:   Child, Adult, Senior
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Ambulant patient

Inclusion Criteria:

  • essential hypertension
  • left ventricular hypertrophy
  • under candesartan treatment

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00607633

Sponsors and Collaborators
Principal Investigator: F. Sonntag, MD Cardiologist, Henstedt-Ulzburg
Study Chair: Andrea Pahor, MD MED Dep., AstraZeneca Germany
  More Information

Responsible Party: Andrea Pahor, AstraZeneca Germany Identifier: NCT00607633     History of Changes
Other Study ID Numbers: NIS-CGE-ATA-2007/2
Study First Received: January 23, 2008
Last Updated: February 5, 2008

Keywords provided by AstraZeneca:
essential hypertension
left ventricular hypertrophy

Additional relevant MeSH terms:
Hypertrophy, Left Ventricular
Vascular Diseases
Cardiovascular Diseases
Pathological Conditions, Anatomical
Heart Diseases
Candesartan cilexetil
Antihypertensive Agents
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists processed this record on May 25, 2017